Lian, Xiaolan
Lin, Yu-Min
Kozono, Shingo
Herbert, Megan K.
Li, Xin
Yuan, Xiaohong
Guo, Jiangrui
Guo, Yafei
Tang, Min
Lin, Jia
Huang, Yiping
Wang, Bixin
Qiu, Chenxi
Tsai, Cheng-Yu
Xie, Jane
Gao, Ziang Jeff
Wu, Yong
Liu, Hekun
Zhou, Xiao Zhen
Lu, Kun Ping
Chen, Yuanzhong
Funding for this research was provided by:
the Construction project of Fujian Medical Center of Hematology (Min201704)
National and Fujian Provincial Key Clinical Specialty Discipline Construction Program, P. R.C
Fujian Province Natural Science Fund for Youths (No. 2016-1-46)
National Institutes of Health grant (R01CA167677)
the National Natural Science Foundation of China (Grant No. 81270571, No. U1205024)
Collaborative Innovation Center for Stem Cells Translational Medicine (Fujian 2011 Program)
Article History
Received: 30 January 2018
Accepted: 29 April 2018
First Online: 30 May 2018
Change Date: 11 July 2018
Change Type: Correction
Change Details: The original article [1] contained minor typesetting errors affecting the following authors: Ziang Jeff Gao, Xiao Zhen Zhou, and Kun Ping Lu.
Ethics approval and consent to participate
: This study was approved by the clinical research ethics committee of Fujian Medical University Union Hospital, Fuzhou, China. Animal work was carried out in compliance with the ethical regulations approved by the Animal Care Committee, Beth Israel Deaconess Medical Center, Boston, USA.
: All the patients that involved in the study have given their consent to publish their individual data.
: Prof. Lu and Dr. Zhou are inventors of Pin1 technology, which was licensed by BIDMC to Pinteon Therapeutics. Both Prof. Lu and Dr. Zhou own equity in, and consult for, Pinteon. Their interests were reviewed and managed by BIDMC in accordance with its conflict of interest policy. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.